Cybin will host an “R&D briefing” at 10 a.m. Eastern time on Thursday, Nov. 30, to release top-line Phase 2 safety and efficacy data for its CYB003 deuterated psilocybin analog. Following the release of the Phase 2 results, Cybin said it will convene “a panel discussion with key opinion leaders on data and study designs, […]
Cybin will host an “R&D briefing” at 10 a.m. Eastern time on Thursday, Nov. 30, to release top-line Phase 2 safety and efficacy data for its CYB003 deuterated psilocybin analog.
Following the release of the Phase 2 results, Cybin said it will convene “a panel discussion with key opinion leaders on data and study designs, the current treatment landscape in depression and the future role of psychedelics.” The panel discussion is scheduled to start at 10:45 a.m., with a Q&A slated to begin at 11:15 a.m.
The panel discussion will feature Dr. Maurizio Fava, chair of the Department of Psychiatry and psychiatrist-in-chief at the Massachusetts General Hospital. Fava is a world leader in the field of depression and clinical psychopharmacology.
The discussion also will include Dr. Gitte M. Knudsen, chair of Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark. Knudsen is a world leader in neuropharmacology and molecular and functional neuroimaging and leads investigator-initiated trials on psychedelics.
Investors, media and others can view a live webcast of the event on Cybin’s website. To register, visit the company’s Events & Presentations page.
CYB003 is a proprietary molecule derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters such as serotonin. CYB003 is being evaluated for the potential treatment of major depressive disorder and alcohol-use disorder. It is the first deuterated psilocybin analog to enter clinical development, according to the company.